PH12014502548A1 - Method for identifying ligands of the ahr receptor having therapeutic sebosuppressive activity, and said ligands - Google Patents
Method for identifying ligands of the ahr receptor having therapeutic sebosuppressive activity, and said ligandsInfo
- Publication number
- PH12014502548A1 PH12014502548A1 PH12014502548A PH12014502548A PH12014502548A1 PH 12014502548 A1 PH12014502548 A1 PH 12014502548A1 PH 12014502548 A PH12014502548 A PH 12014502548A PH 12014502548 A PH12014502548 A PH 12014502548A PH 12014502548 A1 PH12014502548 A1 PH 12014502548A1
- Authority
- PH
- Philippines
- Prior art keywords
- ligands
- substance
- mammal
- sebaceous glands
- skin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/20—Dermatological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12168121.7A EP2664919A1 (fr) | 2012-05-15 | 2012-05-15 | Une méthode pour identifier les ligands du récepteur AhR possédant une activité sebosuppressive thérapeutique |
| PCT/IB2013/053979 WO2013171696A1 (en) | 2012-05-15 | 2013-05-15 | Method for identifying ligands of the ahr receptor having therapeutic sebosuppressive activity, and said ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12014502548A1 true PH12014502548A1 (en) | 2015-01-21 |
Family
ID=46801377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12014502548A PH12014502548A1 (en) | 2012-05-15 | 2014-11-14 | Method for identifying ligands of the ahr receptor having therapeutic sebosuppressive activity, and said ligands |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9480674B2 (https=) |
| EP (2) | EP2664919A1 (https=) |
| JP (1) | JP6254580B2 (https=) |
| KR (1) | KR20150022827A (https=) |
| CN (1) | CN104471391B (https=) |
| AU (1) | AU2013261093A1 (https=) |
| BR (1) | BR112014028307A2 (https=) |
| CA (1) | CA2873191A1 (https=) |
| CO (1) | CO7240392A2 (https=) |
| HK (1) | HK1205252A1 (https=) |
| IL (1) | IL235449A (https=) |
| IN (1) | IN2014DN10283A (https=) |
| MX (1) | MX2014013925A (https=) |
| NZ (1) | NZ702357A (https=) |
| PH (1) | PH12014502548A1 (https=) |
| RU (1) | RU2014150505A (https=) |
| SG (1) | SG11201407405VA (https=) |
| WO (1) | WO2013171696A1 (https=) |
| ZA (1) | ZA201408826B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2082736A1 (fr) | 2008-01-23 | 2009-07-29 | Jean Hilaire Saurat | Composition pharmaceutique à usage topique |
| CN104364394B (zh) * | 2012-03-17 | 2019-02-22 | 加州大学评议会 | 痤疮的快速诊断和个体化治疗 |
| EP2664919A1 (fr) | 2012-05-15 | 2013-11-20 | Jean Hilaire Saurat | Une méthode pour identifier les ligands du récepteur AhR possédant une activité sebosuppressive thérapeutique |
| WO2016022703A1 (en) * | 2014-08-06 | 2016-02-11 | Thesan Pharmaceuticals, Inc. | Agonists of the ahr receptor pathway having sebosuppressive activity and a method for identifying said agonists |
| JP2016150916A (ja) * | 2015-02-17 | 2016-08-22 | 株式会社マンダム | 皮脂分泌抑制剤 |
| EP3167892A1 (en) | 2015-11-10 | 2017-05-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for preventing or treating imflammatory bowel diseases |
| EP3448398A4 (en) | 2016-04-21 | 2019-12-18 | Naked Biome, Inc. | COMPOSITIONS AND METHODS FOR TREATING SKIN DISEASES |
| WO2018065132A1 (en) | 2016-10-04 | 2018-04-12 | Institut National De La Recherche Agronomique | Use of ahr agonist for the preventive or curative treatment of metabolic syndrome and the associated disorders. |
| EP3715471A1 (en) | 2019-03-29 | 2020-09-30 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Ahr signature marker set |
| EP3875098A1 (en) | 2020-03-04 | 2021-09-08 | Institut National De Recherche Pour L'agriculture, L'alimentation Et L'environnement | Use of coprococcus bacteria for the treatment of metabolic syndrome and inflammatory bowel diseases |
| US20240417400A1 (en) * | 2021-10-14 | 2024-12-19 | Galileo Biosystems, Inc. | Aryl hydrocarbon receptor (ahr) modulators and therapeutic uses thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2122923C (en) * | 1991-11-25 | 1999-01-19 | Roy L. Blank | Compositions for regulating skin wrinkles and/or skin atrophy |
| EP1063966A1 (en) * | 1998-03-16 | 2001-01-03 | The Procter & Gamble Company | Methods for regulating skin appearance |
| JP2004515453A (ja) * | 2000-05-05 | 2004-05-27 | ウィスコンシン・アルムナイ・リサーチ・ファウンデーション | 癌を化学療法および放射線療法に付する間に細胞を保護するための組成物および方法 |
| US6902881B2 (en) * | 2000-10-13 | 2005-06-07 | President And Fellows Of Harvard College | Compounds and methods for regulating cell differentiation |
| US20030166583A1 (en) * | 2002-02-22 | 2003-09-04 | Oliver Yoa-Pu Hu | Dermal cytochrome P450 1A inhibitors and enhancers |
| EP1418164A1 (en) | 2002-11-07 | 2004-05-12 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | New stilbene derivatives and their use as aryl hydrocarbon receptor ligand antagonists |
| FR2849597B1 (fr) * | 2003-01-08 | 2006-12-08 | Oreal | Composition cosmetique pour le soin des peaux grasses, contenant un acide gras carboxylique ou l'un de ses derives |
| WO2006072203A1 (fr) * | 2005-01-05 | 2006-07-13 | Oliver Yoa-Pu Hu | Inhibiteur ou promoteur de l’uridinediphosphate-glucuronosyltransferase2b (ugt2b) |
| US20060210524A1 (en) * | 2005-03-18 | 2006-09-21 | Mower Thomas E | Skin care composition |
| US20060210515A1 (en) * | 2005-03-18 | 2006-09-21 | Mower Thomas E | Hair growth formula |
| DE102005056890A1 (de) | 2005-11-28 | 2007-05-31 | Institut für Umweltmedizinische Forschung gGmbH | Kosmetisches Verfahren zur Beeinflussung der Melaninbildung in der Haut |
| KR100798252B1 (ko) * | 2006-01-18 | 2008-01-24 | 주식회사 엘지생활건강 | ｃ-Ｋｉｔ 활성 저해제, 피부미백제 및 이를 함유하는피부미백용 조성물 |
| DE102006011747A1 (de) * | 2006-03-13 | 2007-09-27 | Symrise Gmbh & Co. Kg | Dermatologische und/oder kosmetische Zubereitungen |
| EP1842541A1 (en) * | 2006-03-29 | 2007-10-10 | G.I.M.-Gesellschaft Für Innovative Medizin Gmbh Nfg Ohg | Plant components and extracts and uses thereof |
| US20090208432A1 (en) | 2006-05-03 | 2009-08-20 | Symrise Gmbh & Co., Kg | AH Receptor Antagonists |
| US20080317684A1 (en) * | 2006-09-06 | 2008-12-25 | Isw Group, Inc. | Topical Compositions |
| EP2082736A1 (fr) | 2008-01-23 | 2009-07-29 | Jean Hilaire Saurat | Composition pharmaceutique à usage topique |
| WO2011069860A1 (en) * | 2009-12-08 | 2011-06-16 | Chr. Hansen A/S | Novel use for the treatment of metabolic endotoxemia |
| KR20110139397A (ko) * | 2010-06-23 | 2011-12-29 | 건국대학교 산학협력단 | 다약제 내성 저해 활성을 갖는 5,6-벤조플라본 화합물, 그의 제조 방법 및 이를 유효성분으로 포함하는 다약제 내성 저해용 조성물 |
| CN101953838A (zh) * | 2010-08-13 | 2011-01-26 | 李岱 | 吴茱萸次碱用于治疗银屑病的应用 |
| EP2664919A1 (fr) | 2012-05-15 | 2013-11-20 | Jean Hilaire Saurat | Une méthode pour identifier les ligands du récepteur AhR possédant une activité sebosuppressive thérapeutique |
-
2012
- 2012-05-15 EP EP12168121.7A patent/EP2664919A1/fr not_active Withdrawn
-
2013
- 2013-05-15 JP JP2015512185A patent/JP6254580B2/ja not_active Expired - Fee Related
- 2013-05-15 KR KR20147035211A patent/KR20150022827A/ko not_active Withdrawn
- 2013-05-15 IN IN10283DEN2014 patent/IN2014DN10283A/en unknown
- 2013-05-15 SG SG11201407405VA patent/SG11201407405VA/en unknown
- 2013-05-15 CA CA2873191A patent/CA2873191A1/en not_active Abandoned
- 2013-05-15 NZ NZ702357A patent/NZ702357A/en not_active IP Right Cessation
- 2013-05-15 WO PCT/IB2013/053979 patent/WO2013171696A1/en not_active Ceased
- 2013-05-15 RU RU2014150505A patent/RU2014150505A/ru not_active Application Discontinuation
- 2013-05-15 EP EP13734844.7A patent/EP2850429A1/en not_active Withdrawn
- 2013-05-15 BR BR112014028307A patent/BR112014028307A2/pt not_active IP Right Cessation
- 2013-05-15 CN CN201380025088.6A patent/CN104471391B/zh not_active Expired - Fee Related
- 2013-05-15 MX MX2014013925A patent/MX2014013925A/es unknown
- 2013-05-15 HK HK15105467.6A patent/HK1205252A1/xx unknown
- 2013-05-15 AU AU2013261093A patent/AU2013261093A1/en not_active Abandoned
-
2014
- 2014-11-02 IL IL235449A patent/IL235449A/en not_active IP Right Cessation
- 2014-11-07 US US14/536,507 patent/US9480674B2/en not_active Expired - Fee Related
- 2014-11-14 PH PH12014502548A patent/PH12014502548A1/en unknown
- 2014-12-02 ZA ZA2014/08826A patent/ZA201408826B/en unknown
- 2014-12-12 CO CO14273924A patent/CO7240392A2/es unknown
-
2016
- 2016-10-26 US US15/334,987 patent/US20170042856A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL235449A (en) | 2017-07-31 |
| EP2850429A1 (en) | 2015-03-25 |
| US20170042856A1 (en) | 2017-02-16 |
| MX2014013925A (es) | 2015-05-11 |
| JP2015523553A (ja) | 2015-08-13 |
| CA2873191A1 (en) | 2013-11-21 |
| EP2664919A1 (fr) | 2013-11-20 |
| CN104471391A (zh) | 2015-03-25 |
| IN2014DN10283A (https=) | 2015-08-07 |
| RU2014150505A (ru) | 2016-07-10 |
| KR20150022827A (ko) | 2015-03-04 |
| HK1205252A1 (en) | 2015-12-11 |
| CN104471391B (zh) | 2016-12-07 |
| BR112014028307A2 (pt) | 2017-07-18 |
| CO7240392A2 (es) | 2015-04-17 |
| US20150057343A1 (en) | 2015-02-26 |
| JP6254580B2 (ja) | 2017-12-27 |
| SG11201407405VA (en) | 2014-12-30 |
| ZA201408826B (en) | 2016-09-28 |
| WO2013171696A1 (en) | 2013-11-21 |
| US9480674B2 (en) | 2016-11-01 |
| AU2013261093A1 (en) | 2014-12-18 |
| NZ702357A (en) | 2016-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014502548A1 (en) | Method for identifying ligands of the ahr receptor having therapeutic sebosuppressive activity, and said ligands | |
| de Castilla et al. | Extracellular vesicles as a drug delivery system: A systematic review of preclinical studies | |
| PH12015500276A1 (en) | Treatment of immune-related and inflammatory diseases | |
| Gesteira et al. | Hyaluronan rich microenvironment in the limbal stem cell niche regulates limbal stem cell differentiation | |
| MX380555B (es) | Combinación de anticuerpos anti-gen 3 de la activación de linfocito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para usarse en el tratamiento de tumores. | |
| IN2015DN03826A (https=) | ||
| IN2014CN00675A (https=) | ||
| EP2662914A4 (en) | ANODEACTIVE MATERIAL WITH A FULL PARTICLE CONCENTRATION GRADIENT FOR A LITHIUM SUBSTANCE BATTERY, METHOD OF MANUFACTURING THEREOF, AND LITHIUM SUBSTITUTING BATTERY THEREWITH | |
| EA201890278A1 (ru) | Антитела к pd-l1 | |
| WO2014066486A3 (en) | Biomarker for use in treating anemia | |
| MX366369B (es) | Metodo para un ensayo de deteccion de farmacos basado en celulas y el uso del mismo. | |
| WO2016022994A3 (en) | High affinity pd-1 agents and methods of use | |
| Vazquez Rodriguez et al. | Adipocytes promote early steps of breast cancer cell dissemination via interleukin-8 | |
| SG10201804260QA (en) | Diagnostic assays and kits for detection of folate receptor 1 | |
| Heizmann et al. | Ischemic preconditioning improves postoperative outcome after liver resections: a randomized controlled study. | |
| JP2015523553A5 (https=) | ||
| MA39096B1 (fr) | Anticorps spécifiques à fcrn | |
| EA201400002A1 (ru) | Способы лечения заболеваний сетчатки | |
| EP4470623A3 (en) | Nkt-cell subset for in vivo persistence and therapeutic activity and ppropagation of same | |
| BR112014027905A2 (pt) | anticorpo, célula, ácido nucleico, métodos de identificação de um primeiro anticorpo, de inibição do crescimento de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína, de diagnóstico da presença de um tumor e de distribuição de agente citotóxico. | |
| WO2014134084A3 (en) | Phf20 and jmjd3 compositions and methods of use in cancer immunotherapy | |
| EP2978423A4 (en) | STABLE NANO COMPOSITION WITH DOXORUBICIN, PROCESS FOR THE PREPARATION THEREOF, THE USE THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREWITH | |
| WO2014140362A3 (en) | Lymphocyte biomarkers for determining the clinical response to therapy with mesenschymal stromal cells(msc) | |
| NZ702342A (en) | Pharmaceutical formulation | |
| HK1210038A1 (en) | Nanoconstructs with pharmacological activity |